Study outcomes

Total

History of baseline HF

No history of baseline HF


SU + MET (n = 4674)

DPP4i + MET (n = 9348)

Pvalue

SU + MET (n = 412)

DPP4i + MET (n = 824)

Pvalue

SU + MET (n = 4262)

DPP4i + MET (n = 8524)

Pvalue


HHF

N. of events

70

131
 
44

73
 
26

58
 
Cumulative incidence at 3 years (%)^{a}

1.70 (1.30–2.23)

2.20 (1.82–2.67)
 
11.08 (8.00–15.26)

13.40 (10.53–16.97)
 
0.73 (0.47–1.15)

1.09 (0.81–1.47)
 
HR (95% CI) at 3 years^{b}

1.00

1.39 (1.02–1.90)

0.0369

1.00

1.29 (0.86–1.95)

0.2250

1.00

1.61 (0.97–2.67)

0.0634

Cumulative incidence at 5 years (%)^{a}

2.97 (2.25–3.91)

3.30 (2.46–4.44)
 
19.96 (14.24–27.58)

19.44 (12.38–29.79)
 
1.21 (0.77–1.91)

1.68 (1.15–2.45)
 
HR (95% CI) at 5 years^{b}

1.00

1.26 (0.95–1.67)

0.1132

1.00

1.12 (0.77–1.64)

0.5574

1.00

1.51 (0.96–2.39)

0.0765

 All of cardiovascular and renal outcomes were assessed using a Cox proportional hazards models comparing dipeptidylpeptidase 4 inhibitor with sulfonylurea in combination with metformin after propensity score matching (PMS). PSM was performed by an optimal 2:1 (case: control) matching within a radius of 0.01
 HF, heart failure; DPP4 inhibitor, dipeptidyl peptidase4 inhibitor; HHF, hospitalization for heart failure; N, number; HR, hazard ratio; CI confidence interval; and ESRD, endstage renal disease
 ^{a}Cumulative incidence was calculated based on Kaplan–Meier estimation
 ^{b}Pvalue by cox proportional regression model for clustered data
 ^{c}Adjusted for creatinine
Study outcomes

Total

History of baseline HF

No history of baseline HF


SU + MET (n = 4066)

DPP4i + MET (n = 7635)

Pvalue

SU + MET (n = 333)

DPP4i + MET (n = 613

P

SU + MET (n = 3733)

DPP4i + MET (n = 7022)

Pvalue


ESRD events^{c}

N. of events

11

17
 
2

4
 
9

13
 
Cumulative incidence at 3 years (%)^{a}

0.34 (0.16–0.73)

0.42 (0.25–0.70)
 
0.00

1.23 (0.43–3.51)
 
0.37 (0.17–0.81)

0.35 (0.20–0.63)
 
HR (95% CI) at 3 years^{b}

1.00

1.55 (0.65–3.71)

0.3255
 
–
 
1.00

1.17 (0.47–2.92)

0.7298

Cumulative incidence at 5 years (%)^{a}

0.77 (0.38–1.54)

0.48 (0.29–0.80)
 
1.81 (0.45–7.11)

1.23 (043–3.51)
 
0.67 (0.31–1.48)

0.42 (0.23–0.75)
 
HR (95% CI) at 5 years^{b}

1.00

1.10 (0.54–2.28)

0.7905

1.00

1.81 (0.45–7.11)

0.3977

1.00

1.04 (0.46–2.35)

0.9313

 All of cardiovascular and renal outcomes were assessed using a Cox proportional hazards models comparing dipeptidylpeptidase 4 inhibitor with sulfonylurea in combination with metformin after propensity score matching (PMS). PSM was performed by an optimal 2:1 (case: control) matching within a radius of 0.01
 HF, heart failure; DPP4 inhibitor, dipeptidyl peptidase4 inhibitor; HHF, hospitalization for heart failure; N, number; HR, hazard ratio; CI confidence interval; and ESRD, endstage renal disease
 ^{a}Cumulative incidence was calculated based on Kaplan–Meier estimation
 ^{b}Pvalue by cox proportional regression model for clustered data
 ^{c}Adjusted for creatinine